{"created":"2023-05-15T16:33:25.376982+00:00","id":5649,"links":{},"metadata":{"_buckets":{"deposit":"da221851-93e8-4177-9937-5aa044d6f386"},"_deposit":{"created_by":2,"id":"5649","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"5649"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00005649","sets":["8:9"]},"author_link":["24009","24010","24012","24013","24016","24008","24011","24005","24006","24015","24014","24007"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-07-05","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageStart":"142","bibliographicVolumeNumber":"14","bibliographic_titles":[{"bibliographic_title":"BMC Neurology"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Since there has been no conclusive evidence regarding the treatment of ocular myasthenia, treatment guidelines were recently issued by the European Federation of Neurological Societies/European Neurological Society (EFNS/ENS). However, the therapeutic outcomes concerning the quality-of-life (QOL) of patients with ocular myasthenia are not yet fully understood.Methods: We investigated the therapeutic outcomes of patients with purely ocular myasthenia in a multicenter cross-sectional survey in Japan. To evaluate the severity of ocular symptoms, we used the ocular-quantitative MG (QMG) score advocated by Myasthenia Gravis Foundation of America. We used the Japanese translated version of the MG-QOL15, a self-appraised scoring system.Results: Of 607 myasthenia gravis (MG) patients with an observation-duration of illness ? 2 years, the cases of 123 patients (20%) were limited to ocular muscles (purely ocular myasthenia). During the entire clinical course, 81 patients experienced both ptosis and diplopia, 36 had ptosis alone, and six had diplopia alone. Acetyl-cholinesterase inhibitors and prednisolone were used in 98 and 52 patients, respectively. Treatment improved ocular symptoms, with the mean reduction in ocular-QMG score of 2.3 ± 1.8 points. However, 47 patients (38%) failed to gain minimal manifestation or a better status. Patients with unfavorable outcomes also self-reported severe QOL impairment. Multivariate analyses showed that the pretreatment ocular-QMG score was associated with unfavorable outcomes, but not associated with the patient's QOL.Conclusion: A treatment strategy designed in accord with a patient's ocular presentation must be considered in order to improve ocular symptoms and the patient's QOL.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"BMC Neurology, 14(1), 142; 2014","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"BioMed Central"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1186/1471-2377-14-142","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c 2014 Suzuki et al.; licensee BioMed Central Ltd."},{"subitem_rights":"This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated."}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"14712377","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Suzuki, Shigeaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Murai, Hiroyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Imai, Tomihiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nagane, Yuriko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Masuda, Masayuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tsuda, Emiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Konno, Shingo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Oji, Satoru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakane, Shunya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Motomura, Masakatsu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Suzuki, Norihiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Utsugisawa, Kimiaki"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-21"}],"displaytype":"detail","filename":"BMCNeu14_142.pdf","filesize":[{"value":"442.6 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"BMCNeu14_142.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/5649/files/BMCNeu14_142.pdf"},"version_id":"df6e2f9a-a98b-48de-8d0c-1d671ebfa571"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Ocular myasthenia","subitem_subject_scheme":"Other"},{"subitem_subject":"Ocular-quantitative myasthenia gravis score","subitem_subject_scheme":"Other"},{"subitem_subject":"Quality-of-life","subitem_subject_scheme":"Other"},{"subitem_subject":"Therapeutic outcome","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Quality of life in purely ocular myasthenia in Japan","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Quality of life in purely ocular myasthenia in Japan"}]},"item_type_id":"2","owner":"2","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2014-10-01"},"publish_date":"2014-10-01","publish_status":"0","recid":"5649","relation_version_is_last":true,"title":["Quality of life in purely ocular myasthenia in Japan"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T03:01:39.995609+00:00"}